PHARMACYTE BIOTECH, INC. (PMCB) Current Ratio
- Current ratio · latest quarter: Value 40.30×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 40.30× | Current assets / current liabilities. $30.97M ÷ $768.68K ≈ 40.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 30.97M USD | Assets, Current |
| Current obligations | 768.68K USD | Liabilities, Current |
| Cash and equivalents | 17.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 99.46K USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 390.54K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | $30.97M | $768.68K | $17.74M | $99.46K | (m) | (m) | $390.54K | (m) | 40.30× |
| 2026-04-30 | $37.42M | $826.42K | $18.60M | $254.01K | (m) | (m) | $271.10K | (m) | 45.28× |
| 2026-01-31 | $20.70M | $1.68M | $20.17M | $372.25K | (m) | (m) | $1.20M | (m) | 12.33× |
| 2025-10-31 | $23.02M | $1.58M | $15.41M | $201.19K | (m) | (m) | $1.02M | (m) | 14.60× |
| 2025-07-31 | $19.11M | $1.06M | $13.18M | $261.85K | (m) | (m) | $465.21K | (m) | 18.01× |
| 2025-04-30 | $22.38M | $2.91M | $15.17M | $366.32K | (m) | (m) | $399.20K | (m) | 7.68× |
| 2025-01-31 | $16.96M | $1.19M | $16.38M | $372.63K | (m) | (m) | $484.95K | (m) | 14.20× |
| 2024-10-31 | $21.33M | $4.78M | $20.84M | (m) | (m) | (m) | $348.60K | (m) | 4.47× |
| 2024-07-31 | $32.88M | $7.47M | $32.64M | (m) | (m) | (m) | $553.95K | (m) | 4.40× |
| 2024-04-30 | $50.44M | $7.42M | $50.18M | $0.00 | (m) | (m) | $389.37K | (m) | 6.80× |
| 2024-01-31 | $61.51M | $7.54M | $61.21M | (m) | (m) | (m) | $484.20K | (m) | 8.16× |
| 2023-10-31 | $73.75M | $5.24M | $73.43M | (m) | (m) | (m) | $126.16K | (m) | 14.08× |
| 2023-07-31 | $74.75M | $1.52M | $74.66M | (m) | (m) | (m) | $718.13K | (m) | 49.24× |
| 2023-04-30 | $68.15M | $586.58K | $68.04M | (m) | (m) | (m) | $128.28K | (m) | 116.18× |
| 2023-01-31 | $72.82M | $827.83K | (m) | (m) | (m) | (m) | $445.94K | (m) | 87.97× |
| 2022-10-31 | $77.22M | $1.31M | (m) | (m) | (m) | (m) | $861.28K | (m) | 58.90× |
| 2022-07-31 | $82.26M | $1.09M | (m) | (m) | (m) | (m) | $559.03K | (m) | 75.51× |
| 2022-04-30 | $85.49M | $704.37K | $85.40M | (m) | (m) | (m) | $205.36K | (m) | 121.38× |
| 2022-01-31 | $86.81M | $612.98K | (m) | (m) | (m) | (m) | $92.86K | (m) | 141.63× |
| 2021-10-31 | $87.18M | $186.12K | (m) | (m) | (m) | (m) | $157.04K | (m) | 468.40× |
| 2021-07-31 | $1.51M | $924.97K | (m) | (m) | (m) | (m) | $394.77K | (m) | 1.63× |
| 2021-04-30 | $2.28M | $724.78K | (m) | (m) | (m) | (m) | $172.26K | (m) | 3.14× |
| 2021-01-31 | $3.13M | $640.25K | (m) | (m) | (m) | (m) | $79.16K | (m) | 4.89× |
| 2020-10-31 | $3.81M | $643.65K | (m) | (m) | (m) | (m) | $80.12K | (m) | 5.92× |
| 2020-07-31 | $2.30M | $1.15M | (m) | (m) | (m) | (m) | $384.83K | (m) | 2.00× |
| 2020-04-30 | $1.04M | $1.03M | (m) | (m) | (m) | (m) | $185.84K | (m) | 1.01× |
| 2020-01-31 | $209.19K | $1.02M | (m) | (m) | (m) | (m) | $340.49K | (m) | 0.21× |
| 2019-10-31 | $209.34K | $803.86K | (m) | (m) | (m) | (m) | $164.58K | (m) | 0.26× |
| 2019-07-31 | $477.04K | $606.56K | (m) | (m) | (m) | (m) | $67.55K | (m) | 0.79× |
| 2019-04-30 | $653.40K | $742.85K | (m) | (m) | (m) | (m) | $121.89K | (m) | 0.88× |
| 2019-01-31 | $707.95K | $471.24K | (m) | (m) | (m) | (m) | $133.68K | (m) | 1.50× |
| 2018-10-31 | $937.58K | $662.37K | (m) | (m) | (m) | (m) | $348.64K | (m) | 1.42× |
| 2018-07-31 | $1.95M | $882.94K | (m) | (m) | (m) | (m) | $575.01K | (m) | 2.21× |
| 2018-04-30 | $1.28M | $644.17K | (m) | (m) | (m) | (m) | $352.62K | (m) | 1.99× |
| 2018-01-31 | $1.60M | $887.16K | (m) | (m) | (m) | (m) | $305.59K | (m) | 1.80× |
| 2017-10-31 | $2.79M | $566.96K | (m) | (m) | (m) | (m) | $310.81K | (m) | 4.91× |
| 2017-07-31 | $4.40M | $865.68K | (m) | (m) | (m) | (m) | $628.18K | (m) | 5.08× |
| 2017-04-30 | $3.54M | $580.25K | (m) | (m) | (m) | (m) | $365.60K | (m) | 6.10× |
| 2017-01-31 | $2.49M | $578.27K | (m) | (m) | (m) | (m) | $435.00K | (m) | 4.30× |
| 2016-10-31 | $1.60M | $448.99K | (m) | (m) | (m) | (m) | $300.90K | (m) | 3.57× |
| 2016-07-31 | $2.39M | $456.46K | (m) | (m) | (m) | (m) | $311.63K | (m) | 5.25× |
| 2016-04-30 | $2.03M | $637.64K | (m) | (m) | (m) | (m) | $336.01K | (m) | 3.18× |
| 2016-01-31 | $2.87M | $1.07M | (m) | (m) | (m) | (m) | $697.32K | (m) | 2.70× |
| 2015-10-31 | $2.85M | $1.08M | (m) | (m) | (m) | (m) | $427.21K | (m) | 2.64× |
| 2015-07-31 | $3.86M | $1.16M | (m) | (m) | (m) | (m) | $413.12K | (m) | 3.33× |
| 2015-04-30 | $4.17M | $1.52M | (m) | (m) | (m) | (m) | $496.70K | (m) | 2.74× |
| 2015-01-31 | $997.00K | $378.51K | $958.82K | (m) | (m) | (m) | $375.79K | (m) | 2.63× |
| 2014-10-31 | $1.28M | $276.86K | $1.16M | (m) | (m) | (m) | $272.11K | (m) | 4.62× |
| 2014-07-31 | $3.07M | $371.39K | (m) | (m) | (m) | (m) | $204.37K | (m) | 8.26× |
| 2014-04-30 | $4.19M | $373.67K | (m) | (m) | (m) | (m) | $188.04K | (m) | 11.20× |
| 2014-01-31 | $1.54M | $479.28K | (m) | (m) | (m) | (m) | $167.68K | (m) | 3.21× |
| 2013-10-31 | $472.65K | $990.97K | (m) | (m) | (m) | (m) | $285.73K | (m) | 0.48× |
| 2013-07-31 | $1.80M | $994.15K | $206.04K | (m) | (m) | (m) | $295.57K | (m) | 1.81× |
| 2013-04-30 | $1.85M | $3.80M | (m) | (m) | (m) | (m) | $352.00K | (m) | 0.49× |
| 2013-01-31 | $1.42M | $3.61M | $33.33K | (m) | (m) | $0.00 | $517.39K | (m) | 0.39× |
| 2012-10-31 | $1.29M | $3.50M | $22.70K | (m) | (m) | $0.00 | $463.66K | (m) | 0.37× |
| 2012-07-31 | $1.21M | $4.03M | $24.34K | (m) | (m) | $9.62K | $424.18K | (m) | 0.30× |
| 2012-04-30 | $1.06M | $3.79M | $15.72K | (m) | (m) | $6.85K | $730.07K | (m) | 0.28× |
| 2012-01-31 | $751.91K | $3.28M | $39.08K | (m) | (m) | $2.31K | $572.26K | (m) | 0.23× |
| 2011-10-31 | $606.49K | $3.52M | $14.51K | (m) | (m) | $4.52K | $702.98K | (m) | 0.17× |
| 2011-07-31 | $449.18K | $3.40M | $83.07K | (m) | (m) | $7.62K | $692.55K | (m) | 0.13× |
| 2011-04-30 | $104.75K | $3.39M | $57.20K | (m) | $2.32K | $18.71K | $705.76K | (m) | 0.03× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |